HealthQuill US
A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s and 1990s when millions died of the virus, including many in the United States, according to the World Health Organization.
Drugs Health Pharma

US aid pause to take ‘world back to 1980s, 1990s’ on fighting HIV: WHO 

A US government’s decision to pause funding for HIV programmes in low and middle-income countries will take the world back to the 1980s.

Read More
Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug regulator in the adult population. 
Drugs Health Pharma

AstraZeneca-Daiichi’s breast cancer drug gets broader US nod

Anglo-Swedish AstraZeneca Plc., and Japan’s Daiichi Sankyo’s therapy to treat a certain form of breast cancer has been approved by the US drug.

Read More
Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.
Drugs Health Medical Pharma

Biogen-Eisai’s Alzheimer’s drug gets 4-weekly dosing nod in US

Biogen Inc. and its Japanese partner, Eisai Co. Ltd., announced that the US regulator had approved four-weekly maintenance dosing for its Alzheimer's drug.

Read More
The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may cause hospitalisation and death due to a “rare but serious” allergic reaction.
Drugs Health Medical Pharma

US drug regulator issues warning on certain multiple sclerosis drugs

The US drug regulator has issued its most prominent warning on the use of certain drugs to treat multiple sclerosis, saying it may.

Read More
US adults with attention deficit hyperactivity disorder (ADHD) rose from 10.6% to 15.2% between 2020 and 2023, and Covid-19 pandemic may be a major factor, according to a study published in Psychiatric Research and Clinical Practice.
Health Medical Research

ADHD in US adults rises to 15.2% between 2020 and 2023: Research

US adults with attention deficit hyperactivity disorder (ADHD) rose from 10.6% to 15.2% between 2020 and 2023, and Covid-19 pandemic may be a.

Read More
Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development, automation and software.
Drugs Health Pharma

Daiichi Sankyo sets up robotic lab in US to speed up drug discovery

Daiichi Sankyo, the second-largest pharmaceutical company in Japan in terms of revenue, has set up a laboratory in the US for robotic development,.

Read More
The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.
Climate Health Medical

US to pull out from Paris Agreement that limits global warming 

The US, the world’s second-largest greenhouse gas emitter in the world, will withdraw from a global pact to limit global warming.

Read More
The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19 pandemic.
Health Medical Pharma

US to withdraw from WHO after an executive order from Donald Trump

The US, the World Health Organization’s top donor, has decided to withdraw from the global health body, accusing it of “mishandling” the Covid-19.

Read More
AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.
Drugs Health Pharma

AstraZeneca’s medicine to treat a type of breast cancer gets US nod

AstraZeneca Plc.’s antibody-drug conjugate for treating a certain type of breast cancer got approval from the US drug regulator, the company stated.

Read More
Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug regulator.
Drugs Health Pharma

US drug regulator rejects Atara Biotherapeutics’ rare cancer therapy

Atara Biotherapeutics’ Ebvallotm therapy, for treating patients with a rare cancer that occurs after stem cell transplantation, got rejected by the US drug.

Read More